European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID?19 (SARS?CoV?2) being treated with systemic medication and biologics

The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains the severe acute respiratory syndrome 2 (SARS-CoV-2). severity infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper illness, loss smell taste, pneumonia, multi-organ failure. Risk factors for a lethal course age, male gender, obesity, diabetes, cardiovascular immune suppression.1 At start pandemic, European Task Force on Atopic Dermatitis (ETFAD) shared their position continuation systemic immune-modulating treatments, including immunosuppressive therapy, in atopic dermatitis (AD) patients during time pandemic.2 Safe effective vaccines are urgently needed control achieve herd immunity. More than 50 COVID-19 vaccine candidates currently trials. mRNA lead production antigens host cells, two (RNA-1273 BNT162b2) were recently approved EU member states vaccinate adults against COVID-19. A viral vector-based (AZD1222) has been United Kingdom, but not yet EU. National strategic guidelines recommendations being developed utilized initially those with increased risk course, as well employed critical positions. This article provides ETFAD members regarding vaccination adult AD treated medication biologics. separate discusses how dermatologist may manage allergic issues. Vaccination particularly pneumococcus influenza should be performed recommended guidelines.3 Based listed uncertainties characteristics,3, 7 risk–benefit ratio all appears better an SARS-CoV-2, also patients. There no clear evidence recommend that paused before after vaccination. Temporary 2-week discontinuation methotrexate slightly improved immunogenicity seasonal rheumatoid arthritis,5 this relevant mRNA-based vaccines. Clinicians may, therefore, consider pausing immunosuppressant possible vaccination, typically day until 1 week JAK-inhibitors cyclosporine, weeks azathioprine, possibly improve chances appropriate response. Alternatively, lowest dose used, example 2.5 mg/kg/day azathioprine 7.5 mg/week methotrexate. recommends strictly follow decisions issued local national health authorities each country. While drugs will need case-by-case approach considering specific drug product, inadequate antibody response selected individuals major concern, risk/benefit considered favourable overall population. least 3 between doses, which increases flares if reduced longer periods. Measurement antibodies SARS-CoV-2 can done cases particular importance successful immunization. If live registered future, our use different. We encourage registration ETFAD-supported SECURE-AD register (www.secure-derm.com), captures patients' experiences vaccination.8 thank Dr. Karin Loré, Division Immunology Allergy, Karolinska Institute, Stockholm, Sweden, her kind review article. No funding was obtained work. Thyssen attended advisory boards Eli Lilly, Regeneron, Pfizer, LEO Pharma, Abbvie Sanofi-Genzyme, received speaker honorarium Abbvie, Regeneron research grants Sanofi-Genzyme. Vestergaard investigator, consultant Novartis, Sanofi, Leo Pharma Lilly. Dr Barbarot principal board Pierre Fabre Laboratory, Bioderma, Laboratoire La Roche Posay, Janssen, Amgen, de Bruin-Weller consultant, and/or AbbVie, Almirall, Arena, Galderma, Sanofi-Genzym. Bieber GSK, Celgene, AnaptysBio, MedImmune, Chugai, Fabre, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVerSys, Kymab, Glenmark, Astellas, Daiichi-Sankyo, MenloTx, Dermavant Allmiral. T. speaker, Investigator Allmiral, Böhringer-Ingelheim, Daichi-Sankyo, Dermavant/Roivant, DermTreat, DS RAPT/FLX Bio, Incyte, L´Oréal, Sanofi/Regeneron, UCB. founder non-profit biotech company ‘Davos Biosciences’. Gutermuth Taïeb investigator Johnson Johnson, Modilac, Bioderma Sanofi. Seneschal Weidinger institutional L'Oreal, consultancies lectured at educational events sponsored involved performing clinical trials pharmaceutical industries manufacture used treatment dermatitis. Trzeciak Mead Johnson. Cork Consultant Galapagos, Boots, Reckitt Benckiser, Oxagen, Johnson&Johnson, Hyphens, Procter&Gamble, Menlo Perrigo. Paul Boehringer, Lilly & Co, Merck, UCB pharma, Flohr chief UK Institute Health Research-funded TREAT (ISRCTN15837754) SOFTER (Clinicaltrials.gov: NCT03270566) UK-Irish eczema Systemic Therapy Register (A-STAR; ISRCTN11210918) Union Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/). His department investigator-led Heratizadeh reports personal fees Beiersdorf, Hans Karrer, Nutricia, Meda, outside submitted Darsow gave advice talks grant following companies: ALK-Abello, Bencard, Novartis Sanofi-Regeneron Simon member, AstraZeneca, Torrelo acted advisor participant Mylan. Gelmetti for: Bayer, Galderma Pfizer Pharma. Szalai psoriasis von Kobyletzki De Raeve scientific and/ non-financial support Sanofi-Genzyme Bioderma. Fölster-Holst consultant/Advisor Beiersdorf AG, Neubourg, Inc., Sanofi-Aventis Laboratories, Sanofi-Aventis. Christen-Zaechs advisor, Posey, Procter Gamble Hijnen MedImmune/Astrazeneca, Sanofi Thermo Fisher. Gieler Sebamed organization education programmes Germany Bangert Mylan, Celgene AbbVie Elli Galderma. Spuls past 111017 041217 (unpaid), departmental independent since December NL registry, many e.g. dermatitis, financial compensation paid department/hospital and, Chief (CI) phototherapy registry (TREAT NL) children one main registry. Ring Allergika, Wollenberg Pharmaceuticals, Inc. honoraria Loreal, Deleuran Fabre. independently through authors' academic university hospital affiliations. Chernyshov, Stalder, Svensson, Kunz conflict interest.